On Aug. 16, analyst Douglas Loe with Echelon Wealth Partners commented on RepliCel Life Sciences Inc.'s (RP:TSX.V; REPCF:OTCQB) participation in the ThawSTAR Early Adopter Program, "a cell processing system developed by private CA-based firm Medcision that works with companies in cell therapy processing, for which one of the challenges to sustaining cell viability is managing freeze-thaw cycles." He noted that RepliCel will "specifically use Medcision's ThawSTAR AT2 Automated Cell Thawing Systems (the firm has several models & accessories) for upcoming Phase II trials using RP’s non-bulbar dermal sheath fibroblast therapy RCS-01, aimed at the treatment of skin rejuvenation (the Phase I trial will be completed this month; interim results reported back in Apr/17)."
Loe reacted to the news by writing, "The news while positive logistically to RCS-01 development risk does not impact our model or valuation."
Looking ahead, the analyst wrote, "in the medium term, we are looking for an update on status of RepliCel's CE Mark application for its dermal injector RCI-02, as well as on timeline to commencing aforementioned Phase II clinical trials testing RCS-01 and other hair follicle-derived cell therapies targeting androgenetic alopecia (RCH-01) and tendinopathy (RCT-01), for which early Phase I/II testing was separately encouraging as also reported earlier in F2017."
Echelon has a Speculative Buy rating on RepliCel and a target price of $3.50. Shares of the company are currently trading at around $0.46.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, securities of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: RepliCel Life Sciences. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Analyst Certification | Company: RepliCel Life Sciences Incorporated | Symbol: RP : TSX.V
I, Douglas Loe, hereby certify that the views expressed in the coverage of RepliCel Life Sciences Incorporated accurately reflect my personal views about the subject security or Issuer. I also certify that I have not, am not, and will not receive, directly or indirectly, compensation in exchange for expressing specific recommendations or views.
Does the Analyst or any member of the Analyst’s household have a financial interest in the securities of the subject issuer? If Yes: a) Is it a long or short position? b) What type of security is it? Yes, Long stock.